戴維醫療(300314.SZ)：上半年淨利1984.44萬元 同比降21.37%
格隆匯8月26日丨戴維醫療(300314.SZ)披露2019年半年度報告，報告期內公司實現營業收入1.38億元，同比增長7.88%；歸屬於上市公司股東的淨利潤1984.44萬元，同比下降21.37%；經營活動現金淨流出2106.39萬元，而上年同期為淨流出1557.07萬元；基本每股收益0.0689元，加權平均淨資產收益率2.47%。
報告期內，國內外政治形勢和經濟形勢複雜多變，經濟環境下行，行業競爭加劇，為了更好地應對經濟環境、行業環境帶來的挑戰，公司管理層按照長期發展戰略，緊密圍繞公司年度經營目標，立足主營業務，堅持技術創新，積極響應顧客需求，從研發、生產、銷售到公司治理等多方面提升企業競爭力，使得公司的生產經營總體上保持了穩定發展。
市場營銷方面：報告期內，公司緊緊圍繞年度經營目標，繼續加強營銷團隊建設，加大營銷推廣力度，規範營銷推廣方式，努力建立與客户的長期合作關係並拓展國內外新的市場機會。報告期內公司積極參加了上海及美國、迪拜、印尼、巴西等多個國內外醫療器械展會，並取得了良好的反饋效果。另外，以吻合器為主營業務的全資子公司維爾凱迪，立足於高端，堅持“安全有效、精益創新、保質求量”的質量方針，持續加大對高新技術產品的研發力度，不斷研發出高品質的產品。近年來，憑藉其可靠的品質及優秀的服務，產品獲得了終端市場的認可，逐漸進入了全國各大主流三甲醫院及國際市場。報告期內，維爾凱迪不斷加強銷售力度，持續提升產品的品牌知名度，使得國內外市場獲得進一步拓展。報告期公司實現主營業務收入1.36億元，同比增長11.06%，維爾凱迪實現營業收入1584.74萬元，比上年同期增長167.79%。
技術研發方面：持續技術創新是企業發展的核心動力。報告期內，公司進一步增強研發隊伍實力，繼續堅持以技術創新為引領，以市場需求為導向，不斷加大研發投入，持續加強研發創新，豐富公司產品線，提升產品競爭力。報告期內，公司研發投入共計1623.84萬元，較上年同期增加78.04%。公司及子公司新增獲得專利19項，其中發明專利3項、實用新型專利13項、外觀專利3項，同時新增在研項目4項。此外，嬰兒T-組合復甦器和一次性使用直線型切割吻合器及釘倉處於註冊申請中，維爾凱迪產品一次性使用臍帶剪斷器申報醫療器械註冊獲得受理。截止報告期末，公司及子公司共計獲得註冊證38項、有效專利122項，其中發明專利20項，實用新型專利73項，外觀設計專利29項，在研項目共計31項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
